Alnylam Pharmaceuticals (NASDAQ:ALNY) Lowered to Buy Rating by Wall Street Zen

Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by equities researchers at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued on Tuesday.

Other analysts have also issued reports about the stock. Chardan Capital restated a “buy” rating and set a $425.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 25th. Royal Bank Of Canada dropped their target price on Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating on the stock in a research report on Friday, May 1st. Truist Financial cut their price target on Alnylam Pharmaceuticals from $515.00 to $505.00 and set a “buy” rating for the company in a report on Monday, April 13th. HC Wainwright decreased their target price on shares of Alnylam Pharmaceuticals from $510.00 to $470.00 and set a “buy” rating on the stock in a research report on Monday, June 29th. Finally, Wells Fargo & Company boosted their price objective on Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a research note on Friday, May 1st. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $461.39.

Alnylam Pharmaceuticals Trading Up 1.4%

NASDAQ ALNY traded up $4.52 on Tuesday, hitting $317.56. The company’s stock had a trading volume of 38,850 shares, compared to its average volume of 1,245,290. The firm has a market cap of $42.40 billion, a P/E ratio of 86.51 and a beta of 0.27. Alnylam Pharmaceuticals has a 52-week low of $273.11 and a 52-week high of $495.55. The company’s 50-day simple moving average is $295.49 and its 200 day simple moving average is $327.31. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, beating the consensus estimate of $0.87 by $1.12. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The business had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.12 billion. During the same quarter in the previous year, the business posted ($0.44) earnings per share. The firm’s revenue for the quarter was up 96.4% compared to the same quarter last year. Research analysts predict that Alnylam Pharmaceuticals will post 7.36 EPS for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In related news, Director David E. I. Pyott sold 3,830 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the sale, the director directly owned 1,582 shares of the company’s stock, valued at $473,302.76. This trade represents a 70.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ALNY. MV Capital Management Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $25,000. HM Payson & Co. purchased a new position in Alnylam Pharmaceuticals during the fourth quarter valued at $27,000. Golden State Wealth Management LLC grew its position in shares of Alnylam Pharmaceuticals by 100.0% in the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 36 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth about $29,000. Finally, Ameriflex Group Inc. purchased a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at about $32,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.